12.53
-5.65%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Novocure
From its filings with the US Securities and Exchange Commission
Novocure is based in St. Helier. Its shares trade on Nasdaq under the ticker NVCR. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $655.4m and a net loss of $136.2m. At that date it held total assets of $804.3m and shareholders' equity of $340.5m.
We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device. Our key priorities are to drive commercial adoption of Optune Gio®, Optune Lua®, and Optune Pax®, our commercial TTFields therapy devices, obtain regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.
Optune Gio is approved by the U.S. Food and Drug Administration ("FDA") under the Premarket Approval ("PMA") pathway for the treatment of adult patients with newly diagnosed glioblastoma ("GBM") together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. We also have a CE certificate to market Optune Gio for the treatment of GBM in the European Union ("EU"), as well as approval or local registration in the United Kingdom ("UK"), Japan, Canada and certain other countries.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Oct 2015
- Employees
- 1,605
- Website
- novocure.com ↗
- Head office
- NO. 4 THE FORUM, ST. HELIER
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. William DoyleExecutive Chairman of the Board, since 2009$1.4m
- Ms. Ashley CordovaChief Executive Officer, Director, since 2020$6.1m
- Mr. Christoph BrackmannChief Financial Officer
- Mr. Mukund ParavasthuChief Operating Officer
- Mr. Michael PuriChief Human Resources Officer
- Mr. Francis LeonardExecutive Vice President and President - Novocure Oncology$5.8m
- Mr. Barak Ben-AryeGeneral Counsel$4.8m
- Dr. Nicholas LeupinChief Medical Officer
- Dr. Uri WeinbergChief Innovation Officer$5.1m
- Mr. William VernonLead Independent Director$297,579
- Mr. Asaf DanzigerDirector, since 2002$1.5m
- Ms. Jeryl HillemanIndependent Director$267,579
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 25
- Social
- 91
- Governance
- 60
- Women in the workforce
- 59%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Novocure Ltd has several strengths that contribute to its success in the market. These include:
Weaknesses
- Novocure Ltd also faces certain weaknesses that need to be addressed in order to maintain its position in the market. These weaknesses include:
Opportunities
- Novocure Ltd has identified various opportunities that can contribute to its growth and market expansion. These opportunities include:
Threats
- Novocure Ltd faces several threats that could potentially impact its market position and growth. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.